Related Experiment Videos
Hepatitis C in the setting of HIV co-infection
Mandana Khalili1, Brian W Behm
1University of California San Francisco, San Francisco General Hospital, 1001 Potrero Avenue, NH-3D, San Francisco, CA 94110, USA. khalili@itsa.ucsf.edu
Insights
Hepatitis C virus (HCV) and HIV co-infection is common. While HCV worsens HIV liver disease, its effect on HIV progression is unclear, necessitating further research on HCV treatment safety and efficacy in co-infected patients.
Area of Science:
- Hepatology
- Infectious Diseases
- Virology
Background:
- Hepatitis C virus (HCV) co-infection is prevalent in individuals with Human Immunodeficiency Virus (HIV).
- HIV co-infection can accelerate liver disease progression in HCV patients.
- The impact of HCV on HIV progression remains debated, and HCV may reduce tolerance to HIV antiretroviral therapy due to hepatotoxicity.
Purpose of the Study:
- To review the current understanding of Hepatitis C virus (HCV) therapy in Human Immunodeficiency Virus (HIV)-co-infected individuals.
- To assess the efficacy and safety of HCV treatment in the context of HIV co-infection.
- To highlight the need for further research on potential drug interactions between HCV and HIV antivirals.
Main Methods:
- Literature review of studies investigating HCV treatment in HIV-co-infected patients.
- Analysis of data on virologic response to interferon-based regimens.
- Examination of safety profiles and potential drug-drug interactions.
Main Results:
- HCV virologic response to interferon regimens appears comparable between HCV/HIV co-infected individuals and those with HCV infection alone.
- Limited data exists on the efficacy and safety of newer direct-acting antiviral (DAA) therapies for HCV in this population.
- Potential for increased hepatotoxicity and drug interactions requires careful consideration.
Conclusions:
- HCV treatment in HIV co-infected individuals shows similar virologic responses to interferon-based therapies as in HCV mono-infected patients.
- More research is needed to establish optimal and safe HCV treatment strategies, including DAAs, for co-infected individuals.
- Understanding drug interactions between HCV and HIV medications is crucial for effective management.
Abstract:
Hepatitis C virus (HCV) co-infection is common among HIV-infected individuals and can lead to increased morbidity and mortality in this population. HIV adversely impacts the natural history of HCV disease with higher rates of liver disease progression but the effect of HCV on the natural history of HIV is disputed. Additionally, presence of HCV may decrease tolerability of highly active antiretroviral regimens for HIV treatment due to a potential increase in hepatotoxicity. Currently there is limited information available regarding HCV therapy in the setting of HIV co-infection but the HCV virologic response to interferon regimens appears to be similar to those individuals with HCV infection alone. However, additional information is required to assess the efficacy and safety of HCV therapy including possible interaction of HCV and HIV anti-viral medications in these co-infected individuals.